[HTML][HTML] Trial of upadacitinib and adalimumab for psoriatic arthritis
…, X Wang, L Chen, P Zueger… - … England Journal of …, 2021 - Mass Medical Soc
Background The Janus kinase inhibitor upadacitinib is a potential treatment for psoriatic
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
arthritis. The efficacy and safety of upadacitinib as compared with adalimumab, a tumor necrosis …
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2
…, X Wang, S Zhong, RM McCaskill, P Zueger… - Annals of the …, 2021 - ard.bmj.com
Background Upadacitinib is a Janus kinase inhibitor under evaluation for the treatment of
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …
psoriatic arthritis (PsA). We evaluated upadacitinib in patients with PsA and prior inadequate …
Meeting the challenge of COPD care delivery in the USA: a multiprovider perspective
…, KC Wilson, J Wright, B Yawn, PM Zueger… - The Lancet …, 2016 - thelancet.com
The burden of chronic obstructive pulmonary disease (COPD) in the USA continues to grow.
Although progress has been made in the the development of diagnostics, therapeutics, and …
Although progress has been made in the the development of diagnostics, therapeutics, and …
[HTML][HTML] Upadacitinib in patients with psoriatic arthritis and inadequate response to biologics: 56-week data from the randomized controlled phase 3 SELECT-PsA 2 …
…, X Bu, L Chen, RM McCaskill, P Zueger… - Rheumatology and …, 2021 - Springer
Introduction Upadacitinib is a Janus kinase inhibitor under investigation in patients with
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …
psoriatic arthritis (PsA). This study assessed the 56-week efficacy and safety of upadacitinib in …
Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
…, D Haaland, L Chen, Y Duan, P Zueger… - RMD open, 2021 - rmdopen.bmj.com
Background In SELECT-PsA 1, a randomised double-blind phase 3 study, upadacitinib 15
mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% …
mg and 30 mg were superior to placebo and non-inferior to adalimumab in ≥20% …
LB0001 Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to non-biologic disease …
…, S Jeka, CFP Tena, X Wang, L Chen, P Zueger… - 2020 - ard.bmj.com
Background: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment
of rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (…
of rheumatoid arthritis (RA) and currently under evaluation for treatment of psoriatic arthritis (…
[HTML][HTML] Risk of developing additional immune-mediated manifestations: a retrospective matched cohort study
… Patrick Zueger is an employee of AbbVie and may hold AbbVie stock or stock options.
Vishvas Garg is an employee of AbbVie and may hold AbbVie stock or stock options. Remo …
Vishvas Garg is an employee of AbbVie and may hold AbbVie stock or stock options. Remo …
Op0223 efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (select …
…, M Keiserman, X Wang, S Zhong, P Zueger… - 2020 - ard.bmj.com
Background: Upadacitinib (UPA) is an oral, reversible, JAK inhibitor approved for treatment
of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment …
of moderate to severe rheumatoid arthritis (RA) and currently under evaluation for treatment …
Stakeholder views on pharmacogenomic testing
HN Patel, ID Ursan, PM Zueger… - … : The Journal of …, 2014 - Wiley Online Library
Pharmacogenomics has an important role in the evolution of personalized medicine, and its
widespread uptake may ultimately depend on the interests and perspectives of key players …
widespread uptake may ultimately depend on the interests and perspectives of key players …
Effect of upadacitinib on reducing pain in patients with active psoriatic arthritis or ankylosing spondylitis: post hoc analysis of three randomised clinical trials
…, R Lippe, A Maniccia, D Feng, T Gao, P Zueger… - RMD open, 2022 - rmdopen.bmj.com
Objective Evaluate the effect of upadacitinib on pain outcomes in patients with active psoriatic
arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 …
arthritis (PsA) or ankylosing spondylitis (AS) across 3 randomised trials (SELECT-PsA 1 …